Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer’s Disease International Conference

by Claire | Oct 23, 2022 | Uncategorized

DIADEM PRESENTS CLINICAL DATA AND COMMERCIALIZATION PLANS FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TEST AT 2020 ALZHEIMER’S DISEASE INTERNATIONAL CONFERENCE —Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer’s Disease by Identifying Patients...

New Scientific Publications Show Diadem’s Blood-Based AlzoSure® Biomarker Test Can Predict Which Patients Will Progress to Alzheimer’s Disease Years Before Symptoms Occur

by Claire | Oct 23, 2022 | Uncategorized

NEW SCIENTIFIC PUBLICATIONS SHOW DIADEM’S BLOOD-BASED ALZOSURE® BIOMARKER TEST CAN PREDICT WHICH PATIENTS WILL PROGRESS TO ALZHEIMER’S DISEASE YEARS BEFORE SYMPTOMS OCCUR —Published Studies Explore How a Variant of p53 Contributes to the Development of Alzheimer’s...

Diadem Presents New Data at AAIC® Symposium Showing Its Blood-Based Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease 7 Years Before Symptoms Occur

by Claire | Oct 23, 2022 | Uncategorized

DIADEM PRESENTS NEW DATA AT AAIC® SYMPOSIUM SHOWING ITS BLOOD-BASED BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE 7 YEARS BEFORE SYMPTOMS OCCUR —Analysis of 224 Longitudinal Patient Samples Confirms Diadem’s Prognostic Biomarker Can Predict...

Diadem Presents Clinical Validation Interim Data Confirming Its AlzoSure® Prognostic Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease

by Claire | Oct 23, 2022 | Uncategorized

DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —Longitudinal Data from 482 Patients Validates that AlzoSure® Can Predict Progression to AD Early in...

Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer’s Disease

by Claire | Oct 23, 2022 | Uncategorized

DIADEM AWARDED PATENT IN CHINA FOR ITS ALZOSURE® PROGNOSTIC BIOMARKER TECHNOLOGY THAT ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE —AlzoSure® Accurately Predicts Progression to Alzheimer’s Disease Up to Six Years Earlier than Current Diagnostic Methods—...

Diadem Announces Publication of Clinical Data Showing Its AlzoSure® Biomarker Test Accurately Predicts Progression to Alzheimer’s Disease Six Years Before Diagnosis

by Claire | Oct 23, 2022 | Uncategorized

DIADEM ANNOUNCES PUBLICATION OF CLINICAL DATA SHOWING ITS ALZOSURE® BIOMARKER TEST ACCURATELY PREDICTS PROGRESSION TO ALZHEIMER’S DISEASE SIX YEARS BEFORE DIAGNOSIS —AlzoSure® Predict Identifies Individuals Who Will Progress to Alzheimer’s Disease (AD) Up to Six Years...